id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-349868-lb2jcl8m	Patel, Jay	Cardiovascular Considerations of Experimental Hydroxychloroquine Therapy on Patients Diagnosed With COVID-19: A Case Series Review	2020-07-12		.txt	text/plain	2350	125	51	We present the cases of two COVID-19-positive patients treated with HCQ at our institution, which showed adverse effects of the medication. Hydroxychloroquine (HCQ), a common antimalarial and lupus drug, has been shown to potentially reduce viral carriage and the number of symptomatic days in COVID-19 patients according to an open-label non-randomized French case study of 36 patients [2] . The purpose of this case series was to highlight some of the cardiovascular complications related to HCQ and to engage in a risk-benefit analysis of its use in mild/moderate presentations of COVID-19. We believe these are among the first few cases illustrating adverse cardiovascular effects of the experimental five-day HCQ therapy in mild/moderate presentations of COVID-19. Case 2, considered as low risk, demonstrated how HCQ therapy initiated in an outpatient resulted in an adverse outcome that led to hospital admission.	./cache/cord-349868-lb2jcl8m.txt	./txt/cord-349868-lb2jcl8m.txt